AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39430795 — intervention group
Group type: COMPARATOR
Intervention: Sterile surgical undergloves from 3 other manufacturers
Number of subjects: 0
Study 39430867 — intervention group
Group type: EXPERIMENTAL
Intervention: AI assistance during ultrasound scans
Number of subjects: 57
Study 39431459 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower starting dose of CDK4/6 inhibitors combined with endocrine therapy
Number of subjects: 0
Study 39431459 — intervention group
Group type: COMPARATOR
Intervention: Full dose of CDK4/6 inhibitors combined with endocrine therapy
Number of subjects: 0
Study 39431468 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 0
Study 39431577 — intervention group
Group type: EXPERIMENTAL
Intervention: Sweden and Norway
Number of subjects: 45151
Study 39431577 — intervention group
Group type: COMPARATOR
Intervention: 12 WHO European countries
Number of subjects: 45151
Study 39431909 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal treatment for ADHD, details on dosage and duration not available.
Number of subjects: 0
Study 39431909 — intervention group
Group type: COMPARATOR
Intervention: Control group, details not available.
Number of subjects: 0
Study 39432135 — intervention group
Group type: EXPERIMENTAL
Intervention: Gensini score
Number of subjects: 847
Study 39432135 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined four OCT criteria
Number of subjects: 847
Study 39432135 — intervention group
Group type: EXPERIMENTAL
Intervention: Thin fibrous cap
Number of subjects: 847
Study 39432135 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid arc > 180°
Number of subjects: 847
Study 39432135 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimum lumen area < 3.5 mm
Number of subjects: 847
Study 39432158 — intervention group
Group type: EXPERIMENTAL
Intervention: SH-trehalose
Number of subjects: 312
Study 39432161 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg PO daily
Number of subjects: 113
Study 39432177 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent plasma (CP) treatment
Number of subjects: 475
Study 39432177 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 475
Study 39432189 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast cancer digital tool (in addition to standard care)
Number of subjects: 166
Study 39432189 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 166
Study 39432253 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-μFR
Number of subjects: 260
Study 39432255 — intervention group
Group type: EXPERIMENTAL
Intervention: Revascularisation (REV)
Number of subjects: 1236
Study 39432255 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 1236
Study 39432255 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft surgery (CABG)
Number of subjects: 1236
Study 39432252 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cangrelor
Number of subjects: 550
Study 39432252 — intervention group
Group type: COMPARATOR
Intervention: Crushed ticagrelor (180 mg loading dose)
Number of subjects: 550
Study 39432252 — intervention group
Group type: EXPERIMENTAL
Intervention: Cangrelor
Number of subjects: 550
Study 39432286 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailing of educational materials to both the patient and their prescribing clinician
Number of subjects: 12787
Study 39432286 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailing to the prescribing clinician only
Number of subjects: 12787
Study 39432286 — intervention group
Group type: COMPARATOR
Intervention: Usual care arm
Number of subjects: 12787
Study 39432292 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health worker (CHW) intervention connecting primary care, home, and school settings.
Number of subjects: 626
Study 39432292 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care and school interventions (various programs including Yes We Can Children's Asthma Program, Open Airways For Schools Plus, and school-based asthma therapy).
Number of subjects: 626
Study 39432296 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 cycles of CEV chemotherapy
Number of subjects: 187
Study 39432296 — intervention group
Group type: COMPARATOR
Intervention: 6 cycles of CEV chemotherapy
Number of subjects: 187
Study 39432308 — intervention group
Group type: EXPERIMENTAL
Intervention: Communities That HEAL (CTH) intervention
Number of subjects: 8211506
Study 39432308 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 8211506
Study 39432369 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 39432457 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (4,000 IU capsule daily)
Number of subjects: 56
Study 39432457 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 39432509 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedaquiline 800 mg with rifampicin 600 mg (BE-PEP)
Number of subjects: 313
Study 39432509 — intervention group
Group type: COMPARATOR
Intervention: Rifampicin 600 mg alone (SDR-PEP)
Number of subjects: 313
Study 39432734 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 86
Study 39432734 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 39432738 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritlecitinib 50 mg daily
Number of subjects: 191
Study 39432738 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritlecitinib 200/50 mg
Number of subjects: 191
Study 39432745 — intervention group
Group type: EXPERIMENTAL
Intervention: CBG-002 therapy
Number of subjects: 11
Study 39432808 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic pelvic pain patients
Number of subjects: 564
Study 39432808 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 564
Study 39432867 — intervention group
Group type: EXPERIMENTAL
Intervention: DKN-01 300 mg once every 2 weeks, tislelizumab 200 mg once every 3 weeks, oxaliplatin 130 mg/m2
Number of subjects: 25
Study 39432892 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-guided digital family skills management program
Number of subjects: 37
Study 39432898 — intervention group
Group type: EXPERIMENTAL
Intervention: GDM-Dhulikhel Hospital (GDM-DH) app plus standard care
Number of subjects: 120
Study 39432898 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 120
Study 39432928 — intervention group
Group type: EXPERIMENTAL
Intervention: Excessive GWG in T1
Number of subjects: 221
Study 39432928 — intervention group
Group type: EXPERIMENTAL
Intervention: Excessive GWG in T2
Number of subjects: 221
Study 39432928 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall sample across GWG categories
Number of subjects: 221
Study 39432928 — intervention group
Group type: EXPERIMENTAL
Intervention: Excessive GWG in T1 and T2
Number of subjects: 221
Study 39433132 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs) treatment for 8 weeks
Number of subjects: 909
Study 39433199 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral ovariectomy for ovarian tissue cryopreservation (OTC)
Number of subjects: 28
Study 39433413 — intervention group
Group type: EXPERIMENTAL
Intervention: MI with neurofeedback
Number of subjects: 21
Study 39433413 — intervention group
Group type: EXPERIMENTAL
Intervention: MI alone
Number of subjects: 21
Study 39433413 — intervention group
Group type: COMPARATOR
Intervention: Control (watching movies and visualisation of geometric shapes)
Number of subjects: 21
Study 39433597 — intervention group
Group type: EXPERIMENTAL
Intervention: Click detector using a chronically implanted high density electrocorticographic (ECoG) BCI with coverage of the sensorimotor cortex.
Number of subjects: 1
Study 39433597 — intervention group
Group type: EXPERIMENTAL
Intervention: New click detector trained with less than 15 minutes of data within 1 day.
Number of subjects: 1
Study 39433921 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (2 mA)
Number of subjects: 174
Study 39433921 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS (0 mA)
Number of subjects: 174
Study 39433968 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal fractional flow reserve (rFFR)
Number of subjects: 58
Study 39433968 — intervention group
Group type: EXPERIMENTAL
Intervention: Color Doppler ultrasonography (CDU) parameters
Number of subjects: 58
Study 39434066 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-restricted eating (TRE) for 8 weeks
Number of subjects: 150
Study 39434066 — intervention group
Group type: COMPARATOR
Intervention: Baseline period (no intervention)
Number of subjects: 150
Study 39434066 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-restricted eating (TRE)
Number of subjects: 150
Study 39434072 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual facilitation workshop
Number of subjects: 30
Study 39434107 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and Lifestyle Education Program (ExLE)
Number of subjects: 0
Study 39434107 — intervention group
Group type: COMPARATOR
Intervention: Exercise Program (Ex)
Number of subjects: 0
Study 39434114 — intervention group
Group type: EXPERIMENTAL
Intervention: Fisetin (single oral dose of 20 mg/kg)
Number of subjects: 220
Study 39434114 — intervention group
Group type: EXPERIMENTAL
Intervention: Fisetin (two oral doses of 20 mg/kg each spaced 1 day apart)
Number of subjects: 220
Study 39434114 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study 39434121 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital remote postoperative monitoring
Number of subjects: 28
Study 39434160 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance and endurance circuit training program (exercise group, n=34)
Number of subjects: 62
Study 39434160 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-restricted eating (16:8) combined with training program (combination group, n=28)
Number of subjects: 62
Study 39434171 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted total mesorectal excision (RATME)
Number of subjects: 0
Study 39434171 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic-assisted total mesorectal excision (LATME)
Number of subjects: 0
Study 39434171 — intervention group
Group type: EXPERIMENTAL
Intervention: RATME
Number of subjects: 0
Study 39434171 — intervention group
Group type: COMPARATOR
Intervention: LATME
Number of subjects: 0
Study 39434179 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation programme (ten 1-hour sessions, delivered weekly)
Number of subjects: 120
Study 39434179 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical care without cognitive rehabilitation
Number of subjects: 120
Study 39434191 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactated Ringer's solution (LR) for fluid resuscitation for at least 48 hours
Number of subjects: 720
Study 39434191 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS) for fluid resuscitation for at least 48 hours
Number of subjects: 720
Study 39434193 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-session mindfulness-based intervention (90-minute group-based session with mindfulness practices and psychoeducation, followed by app-based follow-up)
Number of subjects: 0
Study 39434193 — intervention group
Group type: COMPARATOR
Intervention: Education session on dementia care (control group)
Number of subjects: 0
Study 39434193 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-session mindfulness-based intervention
Number of subjects: 0
Study 39434431 — intervention group
Group type: EXPERIMENTAL
Intervention: Cofrogliptin 10 mg
Number of subjects: 475
Study 39434431 — intervention group
Group type: EXPERIMENTAL
Intervention: Cofrogliptin 25 mg
Number of subjects: 475
Study 39434431 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 475
Study 39434549 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevention strategy using the Risk of Recurrence Ulcer Tool
Number of subjects: 0
Study 39434549 — intervention group
Group type: EXPERIMENTAL
Intervention: Early detection strategy using the Risk of Recurrence Ulcer Tool
Number of subjects: 0
Study 39434554 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymer free biolimus coated coronary stent (PF-BCS)
Number of subjects: 914
Study 39434634 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegoprazan-containing sequential therapy
Number of subjects: 406
Study 39434634 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole-containing sequential therapy
Number of subjects: 406
Study 39434728 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% chlorhexidine gluconate (CHG) irrigation
Number of subjects: 100
Study 39434728 — intervention group
Group type: COMPARATOR
Intervention: Conventional antibiotic irrigation (rifampin 600 mg/L of sterile water, gentamicin 80 mg/L of sterile water)
Number of subjects: 100
Study 39435126 — intervention group
Group type: EXPERIMENTAL
Intervention: Esketamine nasal spray (NS) plus SSRI/SNRI
Number of subjects: 696
Study 39435126 — intervention group
Group type: COMPARATOR
Intervention: Real-world treatment (RWT)
Number of subjects: 696
Study 39435124 — intervention group
Group type: EXPERIMENTAL
Intervention: Feel-Good inpatient therapy group
Number of subjects: 10
Study 39435268 — intervention group
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Number of subjects: 0
Study 39435268 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 0
Study 39435321 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin
Number of subjects: 6905
Study 39435321 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6905
Study 39435321 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 vaccination
Number of subjects: 6905
Study 39435387 — intervention group
Group type: EXPERIMENTAL
Intervention: AquOTic intervention (10-week occupational therapy-based aquatic intervention)
Number of subjects: 37
Study 39435392 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-use rhinolaryngoscopes (SURLs)
Number of subjects: 26
Study 39435392 — intervention group
Group type: COMPARATOR
Intervention: Reusable rhinolaryngoscopes (RRLs)
Number of subjects: 26
Study 39435603 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cell-derived exosome-based therapies
Number of subjects: 0
Study 39435603 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cell therapies
Number of subjects: 0
Study 39435603 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparative analysis of therapies utilizing mesenchymal stem cells and exosomes
Number of subjects: 0
Study 39435713 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tenecteplase plus endovascular thrombectomy
Number of subjects: 544
Study 39435713 — intervention group
Group type: COMPARATOR
Intervention: Endovascular thrombectomy alone
Number of subjects: 544
Study 39435908 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 or 2.5 mg parsaclisib orally once daily for 12 weeks
Number of subjects: 25
Study 39436237 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet
Number of subjects: 165
Study 39436237 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MD)
Number of subjects: 165
Study 39436237 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Diet Indicator (HDI)
Number of subjects: 165
Study 39436270 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded motor imagery plus multimodal physical therapy
Number of subjects: 38
Study 39436270 — intervention group
Group type: COMPARATOR
Intervention: Multimodal physical therapy alone
Number of subjects: 38
Study 39436295 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave ablation (MWA)
Number of subjects: 0
Study 39436295 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 0
Study 39436396 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Number of subjects: 64
Study 39436396 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU) waitlist
Number of subjects: 64
Study 39436413 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefilled pen device
Number of subjects: 150
Study 39436413 — intervention group
Group type: COMPARATOR
Intervention: Prefilled syringe
Number of subjects: 150
Study 39436476 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated Systemic Immune-Inflammation Index (SII) > 0.437
Number of subjects: 0
Study 39436476 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated Systemic Immune-Inflammation Index (SII) > 0.437 in patients ≥ 65 years
Number of subjects: 0
Study 39436476 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated Systemic Immune-Inflammation Index (SII) > 0.437 in patients on clopidogrel plus aspirin therapy
Number of subjects: 0
Study 39436553 — intervention group
Group type: EXPERIMENTAL
Intervention: Turkish version of North Star Ambulatory Assessment (T-NSAA)
Number of subjects: 86
Study 39436590 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided cryoablation
Number of subjects: 20
Study 39436590 — intervention group
Group type: COMPARATOR
Intervention: Routine surgical practice (control group)
Number of subjects: 20
Study 39436588 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 39436588 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 39
Study 39436588 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 39
Study 39436588 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol + Ramipril
Number of subjects: 39
Study 39436588 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean Heart Dose (MHD) for patients with no subclinical damage
Number of subjects: 39
Study 39436588 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean Heart Dose (MHD) for patients with subclinical heart damage
Number of subjects: 39
Study 39436613 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2 vaccination (boosted)
Number of subjects: 328
Study 39436613 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated and not up-to-date with COVID-19 vaccination
Number of subjects: 328
Study 39436613 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster 3 (high symptoms, >6 symptoms)
Number of subjects: 328
Study 39436613 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster 1 (low symptoms, <2 symptoms) and Cluster 2 (moderate symptoms, 2-6 symptoms)
Number of subjects: 328
Study 39436684 — intervention group
Group type: EXPERIMENTAL
Intervention: FACET home monitoring system along with standard treatment
Number of subjects: 90
Study 39436684 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 90
Study 39436695 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 diabetes (T1D)
Number of subjects: 30
Study 39436695 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HCs)
Number of subjects: 30
Study 39436905 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational hand therapy intervention
Number of subjects: 49
Study 39436905 — intervention group
Group type: COMPARATOR
Intervention: Traditional occupational therapy approach
Number of subjects: 49
Study 39436905 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 49
Study 39436955 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy for COPD
Number of subjects: 1213
Study 39436955 — intervention group
Group type: COMPARATOR
Intervention: Dual bronchodilation (LAMA + LABA)
Number of subjects: 1213
Study 39437010 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 2666605
Number of subjects: 5
Study 39437136 — intervention group
Group type: EXPERIMENTAL
Intervention: LSM by 2D-SWE
Number of subjects: 2340
Study 39437136 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm (PLEASE)
Number of subjects: 2340
Study 39437217 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (500 mg 3× per day for 20 days before and 10 days after surgery)
Number of subjects: 48
Study 39437217 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 39437217 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin and Placebo
Number of subjects: 48
Study 39437312 — intervention group
Group type: EXPERIMENTAL
Intervention: Deucravacitinib 6 mg once daily
Number of subjects: 220
Study 39437312 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study 39437435 — intervention group
Group type: COMPARATOR
Intervention: Control (24 h high-carbohydrate diet followed by the incremental test)
Number of subjects: 20
Study 39437435 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycogen depletion (glycogen-depletion protocol followed by 24 h low-carbohydrate diet and then the incremental test)
Number of subjects: 20
Study 39437435 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat (24 h high-carbohydrate diet followed by 30 min passive heating and then the incremental test in heat)
Number of subjects: 20
Study 39437546 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax (Ven) 400 mg daily with biweekly Pegcrisantaspase (PegC) 750 IU/m2
Number of subjects: 25
Study 39437708 — intervention group
Group type: EXPERIMENTAL
Intervention: zanubrutinib 160mg twice daily and obinutuzumab 1000mg on cycle 1 day 1, 8, 15 and day 1 of cycles 2-8, followed by venetoclax with weekly dose-ramp up to 400mg daily after 2 cycles
Number of subjects: 25
Study 39437708 — intervention group
Group type: EXPERIMENTAL
Intervention: zanubrutinib, obinutuzumab, and venetoclax (BOVen)
Number of subjects: 25
Study 39437815 — intervention group
Group type: EXPERIMENTAL
Intervention: Gas chromatography-ion mobility spectrometry (GC-IMS) analysis of volatile organic compounds (VOCs) in exhaled breath, blood, and urine.
Number of subjects: 70
Study 39437815 — intervention group
Group type: EXPERIMENTAL
Intervention: Gas chromatography-ion mobility spectrometry (GC-IMS) analysis of VOCs in breath, urine, and blood.
Number of subjects: 70
Study 39438001 — intervention group
Group type: EXPERIMENTAL
Intervention: nal-IRI plus 5-FU/LV
Number of subjects: 277
Study 39438001 — intervention group
Group type: COMPARATOR
Intervention: mFOLFOX
Number of subjects: 277
Study 39438001 — intervention group
Group type: COMPARATOR
Intervention: mFOLFIRI
Number of subjects: 277
Study 39438096 — intervention group
Group type: EXPERIMENTAL
Intervention: DMX-200 120 mg two times per day on background of titratable candesartan commencing at 4 mg two times per day for 28 days.
Number of subjects: 49